Nizatidine
Histamine H2 Antagonists
Famotidine
Food-Drug Interactions
Anti-Ulcer Agents
Sulfoxides
Cisapride
Brief Psychiatric Rating Scale
Cardiography, Impedance
Therapeutic substitution of cimetidine for nizatidine was not associated with an increase in healthcare utilization. (1/24)
OBJECTIVE: To examine changes in healthcare utilization resulting from a formulary switch to cimetidine from nizatidine at the Veterans Affairs Pittsburgh Healthcare System. STUDY DESIGN: A retrospective analysis of administrative and clinical data 6 months before and 6 months after the therapeutic substitution. METHODS: The 704 patients who were switched from nizatidine to cimetidine were included in the study. Administrative data included total and primary care clinic visits, emergency room visits, gastrointestinal (GI)-related radiological studies, and GI endoscopic procedures. Discharge summaries were examined, and rates of total and GI-related hospitalizations were calculated. RESULTS: There was no evidence of increased utilization of healthcare resources during the 6 months after the formulary switch. Estimated monthly pharmaceutical savings for the Veterans Affairs Pittsburgh Healthcare System were $7260. CONCLUSIONS: A formulary switch from nizatidine to cimetidine can be accomplished at significant pharmaceutical cost savings, and this retrospective study suggests that this can be done without increasing other aspects of healthcare resource utilization. (+info)Nizatidine enhances the gastrocolonic response and the colonic peristaltic reflex in humans. (2/24)
Animal studies demonstrate that nizatidine, an H2-receptor inhibitor, may enhance colonic activity independent of its effect on acid secretion. The effect of nizatidine on human colonic motility is unknown. We evaluated the potential prokinetic property of nizatidine in 12 healthy subjects (10 men and 2 women, age 21-46 years). Each subject received either nizatidine (600 mg), famotidine (80 mg, a H2-receptor inhibitor used as a control), or a placebo, on separate days in randomized order at least 3 days apart. Following an overnight fast, a three-lumen catheter fitted with a stimulus balloon and two barostat bags was placed in the descending colon. The gastrocolonic response was tested by antral balloon inflation and the colonic peristaltic reflex was evaluated by colonic distension. Changes in colonic motility were assessed by volume changes in the barostat bags. Antral distension evoked volume-dependent increases in colonic motility, maximal at a 300-ml inflation, as demonstrated by a reduced bag volume. Nizatidine enhanced colonic motility in response to antral distension at 200 and 300 ml, compared with famotidine and placebo. Colonic distension evoked volume-dependent increases in colonic motility proximal to the stimulus balloon. Compared with famotidine and placebo, nizatidine enhanced the ascending and descending contractile limbs of the peristaltic reflex but did not affect relaxation distal to the balloon. In conclusion, nizatidine enhanced the gastrocolonic response and the colonic peristaltic reflex in healthy subjects. Further research on the prokinetic action of nizatidine in the colon may lead to novel treatments for idiopathic constipation. (+info)Effectiveness and safety of nizatidine, 75 mg, for the relief of episodic heartburn. (3/24)
BACKGROUND: The most frequent cause of episodic heartburn is food and beverage ingestion. Nizatidine, an H2-receptor antagonist, is currently approved for non-prescription use in the prevention and relief of heartburn at a dose of 75 mg up to twice a day. METHODS: Two identical studies were carried out to evaluate the efficacy of nizatidine, 75 mg, compared with placebo in treating heartburn in an "at-home" setting. The studies were multicentre, multiple-dose, placebo-controlled, randomized, parallel group design. A total of 994 subjects were randomized to treatment. Adequate relief of heartburn was assessed at 15, 30 and 45 min and 1, 2 and 3 h following a treatment dose. A subject's responses with respect to time to relief and attainment of adequate relief were combined into a derived response profile, the sustained adequate relief score. Adverse experiences were noted throughout the study period. RESULTS: The individual and combined study results showed that nizatidine, 75 mg, relieved heartburn faster and/or more consistently than placebo. The mean sustained adequate relief score, calculated over a subject's first four episodes, was 2.43 in the nizatidine-treated group compared with 2.14 in the placebo group (P < 0.001). Nizatidine-treated subjects attained sustained adequate relief in a significantly (P < 0.001) larger percentage (75%) of their heartburn episodes than did subjects treated with placebo (66%). No serious adverse experiences were associated with nizatidine treatment. CONCLUSION: Nizatidine, 75 mg, is a safe and effective treatment for episodic heartburn. The results showed that subjects taking nizatidine had heartburn relief that was achieved faster and/or more reliably than did subjects taking placebo. (+info)Nizatidine and cisapride enhance salivary secretion in humans. (4/24)
BACKGROUND: Salivation plays an important role in the defence of the oesophageal mucosa against gastric acidic reflux and can be evoked by cholinergic stimulation. Both nizatidine and cisapride have been reported to increase acetylcholine concentrations in the cholinergic system. AIM: To investigate the effect of nizatidine and cisapride on salivary secretion, salivary epidermal growth factor and bicarbonate output. METHODS: The salivary volume and concentration of salivary epidermal growth factor and bicarbonate were measured after the administration of nizatidine (150 mg), famotidine (20 mg) and cisapride (5 mg) in 30 male healthy volunteers. RESULTS: Basal and stimulated salivary secretions were found to be increased after the administration of nizatidine and cisapride. In contrast, salivary secretion was not increased by famotidine. Although epidermal growth factor content was not augmented, nizatidine and cisapride administration also increased the bicarbonate output in mastication-stimulated saliva. CONCLUSIONS: Increased salivary secretion and bicarbonate output induced by nizatidine may be useful for the treatment of patients with gastro-oesophageal reflux disease. (+info)Comparison of the efficacy of pantoprazole vs. nizatidine in the treatment of erosive oesophagitis: a randomized, active-controlled, double-blind study. (5/24)
BACKGROUND: Pantoprazole is a proton pump inhibitor approved for the treatment of erosive oesophagitis and gastro-oesophageal reflux disease. AIM: To compare the efficacy and safety of pantoprazole vs. nizatidine for the treatment of symptomatic gastro-oesophageal reflux disease and endoscopically documented erosive oesophagitis (grade > or = 2). METHODS: A multicentre, double-blind, randomized, active-controlled study (221 patients) was performed to compare 20 and 40 mg pantoprazole daily with nizatidine 150 mg b.d. (maximum, 8 weeks). The primary end-point was endoscopic healing of erosive oesophagitis (grade 1 or 0). The secondary end-point was symptomatic improvement. RESULTS: Healing averaged 61%, 64% and 22% for pantoprazole 20 mg, pantoprazole 40 mg and nizatidine 150 mg, respectively, at 4 weeks, and 79%, 83% and 41% at 8 weeks (P < 0.05, differences between groups at both points). Starting on day 1 of symptom assessment, significantly fewer pantoprazole-treated patients reported night-time heartburn and regurgitation compared with nizatidine-treated patients. Symptoms of gastro-oesophageal reflux disease were completely eliminated in 68% and 65% of patients in the pantoprazole 20-mg and 40-mg groups and in 28% of patients in the nizatidine group at study completion. The difference between each pantoprazole group and the nizatidine group was significant (P < 0.05). CONCLUSIONS: Pantoprazole, at single daily doses of 20 mg and 40 mg for up to 8 weeks, provides more rapid relief of symptoms and superior healing of erosive oesophagitis than nizatidine 150 mg b.d., and is well tolerated. (+info)Meta-analysis: proton pump inhibitor or H2-receptor antagonist for Helicobacter pylori eradication. (6/24)
AIM: To compare H2-receptor antagonists and proton pump inhibitors as adjuvants to triple therapy for Helicobacter pylori eradication. METHODS: H. pylori-infected patients with peptic ulcer were randomized to receive either 300 mg nizatidine or 30 mg lansoprazole plus 1 g amoxicillin and 500 mg clarithromycin taken b.d. for 7 days. H. pylori eradication was assessed 4 weeks after therapy. Using meta-analytical techniques, we combined the results of this study with other randomized controlled comparisons of H2-receptor antagonists and proton pump inhibitors as adjuvants to triple therapy. RESULTS: One hundred and one patients were randomized. H. pylori eradication was 94% (47/50) [95% confidence interval (CI), 83-99%] (intention-to-treat) in the H2-receptor antagonist group vs. 86% (44/51) (95% CI, 74-94%) in the proton pump inhibitor group (P = 0.3). There has been a total of 12 similar studies (1415 patients). The overall efficacy was similar in intention-to-treat analysis: 78% (549/701) with H2-receptor antagonists vs. 81% (575/714) with proton pump inhibitors (odds ratio, 0.86; 95% CI, 0.66-1.12). A non-significant trend favouring H2-receptor antagonist (79% vs. 69%; odds ratio, 1.14; 95% CI, 0.76-1.71; P = 0.5) was seen in the comparison of clarithromycin-containing regimens. In contrast, in non-clarithromycin-containing trials, there was a slight, but significant, advantage with proton pump inhibitors (85% vs. 78%; odds ratio, 0.64; 95% CI, 0.45-0.92; P = 0.02). CONCLUSION: Overall, proton pump inhibitor and H2-receptor antagonist antisecretory agents appear to be similarly effective as adjuvants for H. pylori triple therapy. It is unlikely that the direct anti-H. pylori effect of proton pump inhibitors is responsible for their ability to enhance anti-H. pylori therapy. (+info)Absence of an inhibitory effect of omeprazole and nizatidine on phenytoin disposition, a marker of CYP2C activity. (7/24)
The effects of omeprazole (40 mg orally per day) and nizatidine (300 mg orally per day) on the disposition of phenytoin (4.5 mg kg(-1) p.o. single dose) were studied in 18 healthy, young adult males. Total and unbound plasma concentrations of phenytoin were measured for 48 h after each dose of phenytoin. Neither treatment altered the disposition kinetics of phenytoin, the hydroxylation of which is mediated specifically by cytochromes P450 of the 2C subfamily. (+info)Pantoprazole provides rapid and sustained symptomatic relief in patients treated for erosive oesophagitis. (8/24)
BACKGROUND: Effective symptom control is a primary concern of most heartburn suffers. AIM: To compare the safety and efficacy of pantoprazole, placebo and the H2 antagonist nizatidine in relieving symptoms in patients with erosive oesophagitis. METHODS: Data from two randomized, double-blind studies were pooled. Patients received pantoprazole 10, 20 or 40 mg, or placebo daily (study 1, n = 603), or pantoprazole 20 or 40 mg daily or 150-mg nizatidine b.d. (study 2, n = 243) for either 4 or 8 weeks. Endoscopy was performed at baseline, week 4 and week 8. Persistent absence of symptoms was defined as the first day that no symptoms were reported by the patient on that day or any subsequent study day. RESULTS: A significantly higher percentage (P < 0.05) of pantoprazole patients reported elimination of all symptoms by week 8. Daytime heartburn, night-time heartburn and regurgitation were significantly better controlled with pantoprazole (with a dose-response at most time-points). Absence of symptoms was a powerful predictor of healing; presence of symptoms correlated poorly. CONCLUSION: Pantoprazole is more effective than placebo or nizatidine for controlling heartburn and acid regurgitation in patients with erosive oesophagitis. Relief of GERD symptoms is highly predictive of healing of erosive oesophagitis at 4 and 8 weeks. (+info)Nizatidine is a histamine-2 (H2) receptor antagonist, which is a type of medication that works by reducing the amount of acid produced by the stomach. It is used to treat and prevent ulcers in the stomach and intestines, and to manage conditions where the stomach produces too much acid, such as Zollinger-Ellison syndrome. Nizatidine is also used to treat gastroesophageal reflux disease (GERD) and other conditions in which acid backs up from the stomach into the esophagus, causing heartburn.
The medical definition of Nizatidine is: "A synthetic histamine H2-receptor antagonist that is used in the treatment of gastric ulcers and gastroesophageal reflux disease. It is also used to manage Zollinger-Ellison syndrome."
Histamine H2 antagonists, also known as H2 blockers, are a class of medications that work by blocking the action of histamine on the H2 receptors in the stomach. Histamine is a chemical that is released by the body during an allergic reaction and can also be released by certain cells in the stomach in response to food or other stimuli. When histamine binds to the H2 receptors in the stomach, it triggers the release of acid. By blocking the action of histamine on these receptors, H2 antagonists reduce the amount of acid produced by the stomach, which can help to relieve symptoms such as heartburn, indigestion, and stomach ulcers. Examples of H2 antagonists include ranitidine (Zantac), famotidine (Pepcid), and cimetidine (Tagamet).
Famotidine is a type of medication called an H2 blocker, or histamine-2 receptor antagonist. It works by reducing the amount of acid produced in the stomach. Famotidine is commonly used to treat and prevent ulcers in the stomach and intestines, and to manage conditions where the stomach produces too much acid, such as Zollinger-Ellison syndrome. It is also used to treat gastroesophageal reflux disease (GERD) and other conditions in which acid backs up from the stomach into the esophagus, causing heartburn.
Famotidine is available by prescription and over-the-counter in various forms, including tablets, capsules, and liquid. It is important to take famotidine exactly as directed by a healthcare professional, and to talk to them about any potential risks or side effects.
Gastric acidity determination is a medical test used to measure the amount of acid in the stomach. This test is often performed to diagnose or monitor conditions such as gastritis, gastroesophageal reflux disease (GERD), and Zollinger-Ellison syndrome. The test involves measuring the pH level of the stomach contents using a thin, flexible tube called a catheter that is passed through the nose and down into the stomach. In some cases, a small sample of stomach fluid may also be collected for further testing.
The normal range for gastric acidity is typically considered to be a pH level below 4. A higher pH level may indicate that the stomach is producing too little acid, while a lower pH level may suggest that it is producing too much. Based on the results of the test, healthcare providers can develop an appropriate treatment plan for the underlying condition causing abnormal gastric acidity.
A food-drug interaction is a reaction that occurs when the pharmacological effects of a drug are altered by concurrently consuming a certain food or beverage. This interaction can result in an enhanced or reduced drug effect, and it may change the absorption, distribution, metabolism, or excretion of the drug.
Some food-drug interactions can lead to increased side effects, decreased effectiveness of the medication, or even toxicity. For example, consuming grapefruit juice with certain medications such as statins, calcium channel blockers, and benzodiazepines can increase their blood levels and result in adverse reactions.
It is essential to be aware of potential food-drug interactions and follow the recommended guidelines for medication use, including any specific dietary restrictions or recommendations provided by healthcare professionals.
Anti-ulcer agents are a class of medications that are used to treat and prevent ulcers in the gastrointestinal tract. These medications work by reducing the production of stomach acid, neutralizing stomach acid, or protecting the lining of the stomach and duodenum from damage caused by stomach acid.
There are several types of anti-ulcer agents, including:
1. Proton pump inhibitors (PPIs): These medications block the action of proton pumps in the stomach, which are responsible for producing stomach acid. PPIs include drugs such as omeprazole, lansoprazole, and pantoprazole.
2. H-2 receptor antagonists: These medications block the action of histamine on the H-2 receptors in the stomach, reducing the production of stomach acid. Examples include ranitidine, famotidine, and cimetidine.
3. Antacids: These medications neutralize stomach acid and provide quick relief from symptoms such as heartburn and indigestion. Common antacids include calcium carbonate, magnesium hydroxide, and aluminum hydroxide.
4. Protective agents: These medications form a barrier between the stomach lining and stomach acid, protecting the lining from damage. Examples include sucralfate and misoprostol.
Anti-ulcer agents are used to treat conditions such as gastroesophageal reflux disease (GERD), peptic ulcers, and Zollinger-Ellison syndrome. It is important to take these medications as directed by a healthcare provider, as they can have side effects and interactions with other medications.
Sulfoxides are organic compounds characterized by the functional group consisting of a sulfur atom bonded to two oxygen atoms and a carbon atom. The general structure is R-S(=O)O-R', where R and R' represent alkyl or aryl groups. They are often formed by the oxidation of sulfides, which contain a sulfur atom bonded to two carbon atoms. Sulfoxides have a trigonal pyramidal geometry at the sulfur atom due to the presence of two electron-withdrawing oxygen atoms. They exhibit properties of both polar and nonpolar compounds, making them useful as solvents and intermediates in organic synthesis.
Cisapride is a medication that was used to treat gastrointestinal motility disorders, such as gastroparesis and constipation. It belongs to a class of drugs called "prokinetic agents" which work by increasing the contractions or movements of the muscles in the digestive tract, thereby helping to move food and waste through the system more efficiently.
Cisapride was first approved for use in the United States in 1993, but its use was later restricted due to concerns about serious side effects, including cardiac arrhythmias (irregular heartbeats) and interactions with other medications. In 2000, the U.S. Food and Drug Administration (FDA) requested that cisapride be withdrawn from the market due to these safety concerns.
While cisapride is no longer available for use in many countries, it may still be used in some cases under strict guidelines and monitoring conditions. It is important to note that the use of cisapride should only be initiated and monitored by a healthcare professional, and patients should inform their doctor about all other medications they are taking to avoid potential interactions.
The Brief Psychiatric Rating Scale (BPRS) is a widely used clinician-rated scale for assessing the severity of psychopathology in individuals with mental illness. It consists of 18 items, each rated on a 7-point scale (1=not present to 7=extremely severe), that measure various symptoms such as depression, anxiety, hostility, hallucinations, and unusual thoughts. The BPRS is often used in research and clinical settings to monitor treatment response and symptom changes over time.
Impedance cardiography is a non-invasive method to measure cardiac output and systemic vascular resistance. It uses low-frequency electrical currents passed through the thorax to measure changes in impedance or resistance to flow during each heartbeat. This allows for the calculation of stroke volume and cardiac output. Impedance cardiography can provide continuous, real-time monitoring of cardiovascular function, making it useful in critical care settings and for tracking changes in patients with heart failure or other cardiovascular conditions.
Famotidine5
- Axid (nizatidine), Pepcid (famotidine), Tagamet (cimetidine) and Zantac (ranitidine) are some examples. (canyonranch.com)
- 2. Rebound hypersecretion after H2-antagonist withdrawal--a comparative study with nizatidine, ranitidine and famotidine. (nih.gov)
- 4. Comparative study of the H2-receptor antagonists cimetidine, ranitidine, famotidine and nizatidine on the rabbit stomach fundus and sigmoid colon. (nih.gov)
- 5. Comparison of the effects of placebo, ranitidine, famotidine and nizatidine on intragastric acidity by means of continuous pH recording. (nih.gov)
- 12. Head-column field-amplified sample stacking in capillary electrophoresis for the determination of cimetidine, famotidine, nizatidine, and ranitidine-HCl in plasma. (nih.gov)
Cimetidine3
- Despite its metabolism by the P450 system, nizatidine does not result in significant inhibitor or induction of the enzymes and thus is less likely to cause drug-drug interactions than cimetidine. (nih.gov)
- Nizatidine has been in use for a shorter time than cimetidine or ranitidine and remains unknown whether there is cross reactivity in hepatic injury between nizatidine and other H2 blockers. (nih.gov)
- 20. Effects of successive doses of nizatidine, cimetidine and ranitidine on serum gastrin level and gastric acid secretion. (nih.gov)
Issued a nizatidine recall2
- Another manufacturer, Amneal Pharmaceutical, issued a nizatidine recall in April 2020. (justicecounts.com)
- A major Canadian pharmaceutical company has issued a nizatidine recall, the latest in a string of cancer concerns related to the popular heartburn medication. (justicecounts.com)
20202
- In January 2020, Mylan Pharmaceuticals issued a voluntary recall of certain lots of nizatidine after the heartburn medication tested positive for NDMA, a chemical which may cause cancer. (justicecounts.com)
- An initial nizatidine recall was issued by Mylan in the United States in early 2020 after testing found elevated levels of NDMA, a potentially cancer-causing chemical. (justicecounts.com)
NDMA6
- While Mylan has not received any reports of adverse events related to these batches to date, this product is being voluntarily recalled due to detected trace amounts of an impurity N-nitrosodimethylamine (NDMA) contained in the API Nizatidine, USP, manufactured by Solara Active Pharma Sciences Limited. (fda.gov)
- These recalls and potential NDMA contamination may result in many nizatidine cancer lawsuits. (justicecounts.com)
- The FDA has said that Amneal Pharmaceuticals is recalling three lots of nizatidine oral solution at the consumer level due to potential NDMA contamination. (europeanpharmaceuticalreview.com)
- Now, nizatidine, another medication used by those here in Ohio and elsewhere for gastrointestinal issues, has been added to the list of medications recalled for NDMA. (kelley-ferraro.com)
- In the wake of findings that Zantac may cause cancer due to NDMA contamination, scientists, doctors and patients are increasingly worried about another heartburn medication, nizatidine. (justicecounts.com)
- On Wednesday, the FDA also announced that the drug company Mylan has recalled three lots of another antacid, nizatidine, which were also found to contain trace amounts of NDMA. (nbcnews.com)
Axid AR2
- Over-the-counter preparations of nizatidine are usually tablets of 75 mg (Axid-AR). (nih.gov)
- It is marketed as Axid AR or nizatidine. (canadianpharmacyonline.com)
300mg2
- Oral administration of 75 to 300mg of nizatidine increased betazole-stimulated secretion of intrinsic factor. (nih.gov)
- Mylan N.V. (NASDAQ: MYL) today announced that its U.S. based Mylan Pharmaceuticals business is conducting a voluntary nationwide recall, to the consumer level, of three lots of Nizatidine Capsules, USP (including the 150mg and 300mg strengths). (fda.gov)
Ranitidine and nizatidine1
- 1. Risk of Cancer in Association with Ranitidine and Nizatidine vs Other H2 Blockers: Analysis of the Japan Medical Data Center Claims Database 2005-2018. (nih.gov)
Medication3
- The hepatic injury caused by nizatidine is usually rapidly reversible with stopping the medication, but an instance of severe hepatitis with incomplete recovery and cirrhosis has been reported (Case 1). (nih.gov)
- Brand names of the generic medication nizatidine include Tazac and Axid . (justicecounts.com)
- Nizatidine is the potent ingredient in this medication. (canadianpharmacyonline.com)
Capsules2
- Nizatidine is available by prescription in capsules of 150 and 300 mg in several generic forms and in both oral and parenteral forms under the brand name Axid. (nih.gov)
- Recalled batches include nizatidine capsules sold in bottles of 60 with an expiration date of May, as well as nizatidine capsules sold in bottles of 30 with an expiration date of January. (nbcnews.com)
Histamine7
- Nizatidine is a histamine H2 receptor antagonist that inhibits stomach acid production, and is commonly used in the treatment of peptic ulcer disease and gastroesophageal reflux disease. (wikipedia.org)
- Nizatidine, USP is a histamine H 2 -receptor antagonist. (nih.gov)
- Nizatidine is a competitive, reversible inhibitor of histamine at the histamine H 2 -receptors, particularly those in the gastric parietal cells. (nih.gov)
- Nizatidine is a histamine type 2 receptor antagonist (H2 blocker) which is widely used for treatment of acid-peptic disease and heartburn. (nih.gov)
- Nizatidine (nye za' ti deen) was the fourth histamine type 2 receptor blocker (H2 blocker) introduced into clinical practice in the United States and is a commonly used agent for treatment of duodenal and gastric ulcer and gastroesophageal reflux disease. (nih.gov)
- Nizatidine (brand names include Tazac, Axid and Azor ) is a histamine H2 receptor antagonist that inhibits stomach acid production. (justicecounts.com)
- Nizatidine competitively inhibits histamine at the H2 receptor of the gastric parietal cells, resulting in reductions in gastric acid secretion, gastric volume, and hydrogen concentrations. (medscape.com)
Mylan1
- The nizatidine recall was voluntarily issued by Mylan Pharmaceuticals Inc., a pharmaceutical company based here in the United States. (kelley-ferraro.com)
Receptor2
- Aim: The aim of the study was to develop gastroretentive floating pellets containing H2 â€"receptor antagonist, nizatidine which is primarily absorbed from stomach and has low oral bioavailability. (asiapharmaceutics.info)
- 15. Nocturnal acid suppression with a new H2 receptor antagonist--nizatidine. (nih.gov)
Lilly2
- Nizatidine was developed by Eli Lilly, and was first marketed in 1988. (wikipedia.org)
- Nizatidine was approved by the FDA in 1988 after being developed by Eli Lilly. (justicecounts.com)
Stomach4
- Nizatidine is used to treat and prevent the recurrence of ulcers and to treat other conditions where the stomach makes too much acid. (medlineplus.gov)
- Nizatidine also is used to treat or prevent occasional heartburn, acid indigestion, or sour stomach. (medlineplus.gov)
- If symptoms of heartburn, acid indigestion, or sour stomach last for longer than 2 weeks while taking nizatidine, stop taking it and call your doctor. (medlineplus.gov)
- Nizatidine is used for short-term treatment of stomach ulcers as well as heartburn caused by gastroesophageal reflux disease, the FDA wrote on its website . (nbcnews.com)
Zantac1
- The recalls of nizatidine follow widespread Zantac cancer warnings. (justicecounts.com)
Nocturnal1
- Nizatidine significantly inhibited nocturnal gastric acid secretion for up to 12 hours. (nih.gov)
Decreases2
- Moderate to severe renal impairment significantly prolongs the half-life and decreases the clearance of nizatidine. (nih.gov)
- blessed thistle decreases effects of nizatidine by pharmacodynamic antagonism. (medscape.com)
Gastric9
- Nizatidine is used to treat duodenal ulcers, gastric ulcers, and gastroesophageal reflux disease (GERD/GORD), and to prevent stress ulcers. (wikipedia.org)
- Nizatidine also significantly inhibited gastric acid secretion stimulated by food, caffeine, betazole, and pentagastrin (Table 1). (nih.gov)
- Oral administration of 75 to 300 mg of nizatidine did not affect pepsin activity in gastric secretions. (nih.gov)
- The listed indications for nizatidine are duodenal and gastric ulcer disease, gastroesophageal reflux and prevention of stress ulcers. (nih.gov)
- Nizatidine is indicated for the short-term treatment (up to 8 weeks) of active duodenal ulcers and active benign gastric ulcers, as maintenance therapy for duodenal ulcer patients for up to one year, and for up to 12 weeks for the treatment of endoscopically diagnosed esophagitis and associated heartburn due to gastroesophageal reflux disease (GERD). (fda.gov)
- nizatidine will decrease the level or effect of atazanavir by increasing gastric pH. (medscape.com)
- nizatidine will decrease the level or effect of itraconazole by increasing gastric pH. (medscape.com)
- nizatidine will decrease the level or effect of neratinib by increasing gastric pH. (medscape.com)
- nizatidine will decrease the level or effect of pazopanib by increasing gastric pH. (medscape.com)
Blockers1
- Chronic therapy with nizatidine and other H2 blockers is associated with minor elevations in serum aminotransferase levels in 1% to 4% of patients, but similar rates have been reported in placebo recipients. (nih.gov)
Drugs1
- tell your doctor and pharmacist if you are allergic to nizatidine or any other drugs. (medlineplus.gov)
Serum gastrin1
- Nizatidine had no effect on basal serum gastrin. (nih.gov)
Generic3
- If you've been diagnosed with cancer after taking prescription nizatidine (Tazac, Axid, or Azor) or generic nizatidine, contact the nizatidine cancer attorneys at Riddle & Brantley for a FREE consultation by calling 1-800-525-7111. (justicecounts.com)
- The former is manufactured by Pendopharm as a product of the CanadaOur generic, Nizatidine, is made by UK Generic Mfr. (canadianpharmacyonline.com)
- In addition, you can always purchase Nizatidine, the generic alternative, instead of Axid. (qualityprescriptiondrugs.com)
Duodenal2
Medications1
- Recalls have been issued for certain nizatidine medications. (justicecounts.com)
Pharmaceuticals2
- The US Food and Drug Administration (FDA) has announced that Amneal Pharmaceuticals, LLC is voluntarily recalling three lots of its nizatidine oral solution, 15mg/mL (75mg/5mL), packaged in 480mL bottles. (europeanpharmaceuticalreview.com)
- The nizatidine oral solution was distributed by Gemini Laboratories, LLC, a wholly owned subsidiary of Amneal Pharmaceuticals. (europeanpharmaceuticalreview.com)
Recalls1
- In the wake of these recalls, Nizatidine manufacturers may face potential lawsuits by nizatidine cancer lawyers alleging negligence and claims that they ignored warning signs. (justicecounts.com)
Acid1
- 16. The 24-hour acid suppression profile of nizatidine. (nih.gov)
Patients2
- Rare instances of clinically apparent liver injury have been reported in patients receiving nizatidine, but too few cases have been reported to characterize a typical time to onset or pattern of injury. (nih.gov)
- Patients treated with nizatidine are prescribed to take it from eight weeks to one year depending on the circumstances and their medical conditions. (kelley-ferraro.com)
Amounts1
- Because of the low levels of nizatidine in breastmilk, amounts ingested by the infant are small and would not be expected to cause any adverse effects in breastfed infants. (nih.gov)
Liver Injury1
- Nizatidine has been linked to rare instances of clinically apparent acute liver injury. (nih.gov)
19881
- Nizatidine was first approved for use in the United States in 1988 and is now available both by prescription and over-the-counter. (nih.gov)
Inhibition2
- nizatidine will decrease the level or effect of infigratinib by inhibition of GI absorption. (medscape.com)
- 10. [Inhibition of 24-hour acidity by nizatidine]. (nih.gov)
Capsule2
- Nizatidine comes as a tablet and capsule to take by mouth. (medlineplus.gov)
- Each nizatidine capsule USP contains for oral administration corn starch, magnesium stearate, povidone, pregelatinized starch, sodium starch glycolate and 150 mg (0.45 mmol) or 300 mg (0.91 mmol) of nizatidine USP. (nih.gov)
Oral3
- The oral bioavailability of nizatidine is unaffected by concomitant ingestion of propantheline. (nih.gov)
- More than 90% of an oral dose of nizatidine is excreted in the urine within 12 hours. (nih.gov)
- Read user comments about the side effects, benefits, and effectiveness of nizatidine oral. (webmd.com)
Lots1
- The affected nizatidine lots were distributed directly to wholesalers who further distributed to retail pharmacies and consumers nationwide in the USA. (europeanpharmaceuticalreview.com)
Drug2
- Nizatidine is metabolized by the microsomal P450 drug metabolizing enzymes and injury may be the result of its activation to a toxic intermediate. (nih.gov)
- Have you taken the common heartburn drug nizatidine and been diagnosed with cancer? (justicecounts.com)
Treatment1
- 17. Nizatidine versus ranitidine in the treatment of peptic ulcer disease: report on the Dutch investigation as part of a European multicentre trial. (nih.gov)
Cancer8
- A nizatidine cancer lawyer may be able to help with a potential nizatidine cancer lawsuit. (justicecounts.com)
- Call 1-800-525-7111 today and let's review your nizatidine cancer claim. (justicecounts.com)
- These cancers may qualify you for a nizatidine cancer lawsuit. (justicecounts.com)
- A nizatidine cancer lawyer at Riddle & Brantley may be able to help. (justicecounts.com)
- For a FREE consultation with an experienced nizatidine cancer lawyer, please call 1-800-525-7111. (justicecounts.com)
- You may be eligible for a nizatidine claim and our nizatidine cancer attorneys would love to help you get justice if we can. (justicecounts.com)
- Why Riddle & Brantley for your nizatidine cancer lawsuit? (justicecounts.com)
- We believe Justice Counts for those diagnosed with cancer potentially as a result of contaminated nizatidine and we would love to help with a potential nizatidine lawsuit or claim however we can. (justicecounts.com)